MS in the Media - 22 June 2018

NICE has approved Ocrevus (ocrelizumab) as a treatment for people with active relapsing remitting MS who are unable to take alemtuzumab (Lemtrada). NICE's decision covers England and Wales. Northern Ireland usually follows NICE decisions. The SMC are expected to publish their guidance for Scotland in July

Source: Pharma Times

MS Trust link: Ocrelizumab (Ocrevus) approved for relapsing remitting MS in England and Wales

The Home Secretary has announced a review of the use and potential harms of medicinal cannabis.  This could lead to a rescheduling of its use as a treatment. The government have no plans to legalise or decriminalise the drug for recreational use.

Source: Guardian
Source: Daily Telegraph

MS Trust link: Cannabis

People receiving the highest level of personal independence payment (PIP) and who have conditions, such as MS, that are not expected to improve, will in future only need a 'light touch review' every ten years

Source: Guardian

MS Trust link: Benefits

Results have been published from a study that failed to show Tysabri (natalizumab) was effective in secondary progressive MS based on the primary outcome of lower limb function, though did show an effect on upper limbs

Source: MS Research Australia

MS Trust link: Tysabri (natalizumab)

Swedish research found that people who had had stress disorders were 46% more likely to develop an autoimmune condition (including MS). Early treatment for stress reduced the risk.

Source: Business Insider

MS Trust link: Stress